New Data on EMA401 in Model of Diabetic Neuropathy Presented at 21st Annual NEURODIAB Meeting

Bio-Medicine.Org

MELBOURNE, Australia, September 12, 2011 /PRNewswire/ --

EMA401 Shown to Improve Nerve and Neurovascular Function

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy. EMA401 is an angiotensin II type 2 (AT2) receptor antagonist currently in clinical development for a number of neuropathic pain indications.

The new data were presented at the 21st annual meeting of the Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes, NEURODIAB, on the 11th September by Professors Norman Cameron and Mary Cotter of the University of Aberdeen.

Diabetic neuropathy is a side effect of diabetes that is characterized by the peripheral nerves not functioning properly. Patients present with symptoms that include pain but can also include sensory loss and reduced reflex. Diminished nerve conduction velocities resulting from damage to the peripheral nervous system have also been linked to other serious side effects of diabetes such as ulcers of the feet and legs which can ultimately lead to amputation.

In the new study, initiated by Spinifex Pharmaceuticals, EMA401 was shown to correct motor and sensory nerve conduction velocity (NCV) in an established animal model of diabetes. EMA401 also reduced pain and heat sensitivity and corrected sciatic nerve nutritive blood flow. EMA401 was effective at a dose of 1 mg/kg/day and no CNS side effects were observed, consistent with earlier studies at this and higher doses.

Spinifex Pharmaceuticals CEO Tom McCarthy said: "The discovery that AT2 receptor antagonists offer an innovative approach to the treatment of neuropathic and inflammatory pain was originally made by Professor Maree Smith at The University of Queensland and we have good earlier data on the impact of EMA401 on neuropathic pain in pre-clinical models. This new study we initiat
'/>"/>

SOURCE [1]

Source URL (retrieved on *08/20/2014 - 11:23am*):
http://www.mdtmag.com/news/2011/09/new-data-ema401-model-diabetic-neuropathy-presented-21st-annual-neurodiab-meeting?qt-most_popular=0

Links:
[1] http://www.bio-medicine.org/medicine-technology-1/New-Data-on-EMA401-in-Model-of-Diabetic-Neuropathy-Presented-at-21st-Annual-NEURODIAB-Meeting-20144-1/